BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21609295)

  • 1. CCR1 as a target for multiple myeloma.
    Vallet S; Anderson KC
    Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
    Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
    Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of CCR1 antagonists for multiple myeloma.
    Karash AR; Gilchrist A
    Future Med Chem; 2011 Nov; 3(15):1889-908. PubMed ID: 22023033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
    Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
    Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
    Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
    Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR1 blockade and myeloma bone disease.
    Sebag M
    Blood; 2012 Aug; 120(7):1351-2. PubMed ID: 22899473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.
    Gilchrist A; Gauntner TD; Fazzini A; Alley KM; Pyen DS; Ahn J; Ha SJ; Willett A; Sansom SE; Yarfi JL; Bachovchin KA; Mazzoni MR; Merritt JR
    Br J Pharmacol; 2014 Nov; 171(22):5127-38. PubMed ID: 24990525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.
    Gilchrist A; Echeverria SL
    Front Endocrinol (Lausanne); 2022; 13():846310. PubMed ID: 35399952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
    Vallet S; Raje N; Ishitsuka K; Hideshima T; Podar K; Chhetri S; Pozzi S; Breitkreutz I; Kiziltepe T; Yasui H; Ocio EM; Shiraishi N; Jin J; Okawa Y; Ikeda H; Mukherjee S; Vaghela N; Cirstea D; Ladetto M; Boccadoro M; Anderson KC
    Blood; 2007 Nov; 110(10):3744-52. PubMed ID: 17715391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.
    Liu L; Yu Z; Cheng H; Mao X; Sui W; Deng S; Wei X; Lv J; Du C; Xu J; Huang W; Xia S; An G; Zhou W; Ma X; Cheng T; Qiu L; Hao M
    Sci Rep; 2020 Nov; 10(1):20508. PubMed ID: 33239656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
    Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of CCL3 on osteoblast in myeloma bone disease].
    Zhao S; Fu R; Liu H; Wang Y; Li L; Liu C; Zhang T; Ding S; Gao S; Ruan E; Qu W; Wang H; Wang X; Wu Y; Song J; Liu H; Guan J; Shao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):623-7. PubMed ID: 25052606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment strategies for bone disease.
    Roodman GD
    Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidences of the cooperative role of the chemokines CCL3, CCL4 and CCL5 and its receptors CCR1+ and CCR5+ in RANKL+ cell migration throughout experimental periodontitis in mice.
    Repeke CE; Ferreira SB; Claudino M; Silveira EM; de Assis GF; Avila-Campos MJ; Silva JS; Garlet GP
    Bone; 2010 Apr; 46(4):1122-30. PubMed ID: 20053385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
    Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
    Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of C-C chemokine receptors 1 and 5 and CCL3/macrophage inflammatory protein-1alpha in the cutaneous Arthus reaction: possible attenuation of their inhibitory effects by compensatory chemokine production.
    Yanaba K; Mukaida N; Matsushima K; Murphy PM; Takehara K; Sato S
    Eur J Immunol; 2004 Dec; 34(12):3553-61. PubMed ID: 15517609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.